MoonLake Immunotherapeutics
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | -102.2% | -102.2% | -65.0% |
| FY2023 | -7.3% | -7.3% | -6.8% |
| FY2024 | -26.6% | -26.6% | -24.9% |
| FY2025 | -74.7% | -60.0% | -53.6% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | -102.2% | -102.2% | -65.0% |
| FY2023 | -7.3% | -7.3% | -6.8% |
| FY2024 | -26.6% | -26.6% | -24.9% |
| FY2025 | -74.7% | -60.0% | -53.6% |